Dose setting test of insulin secretion inhibitor.

Dose setting test of insulin secretion inhibitor(DIAZOXIDE) for anti-obesity effect.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071200028

Enrollment

Registered

2020-08-28

Start date

2020-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visceral obesity with hyperinsulinemia.

Interventions

Oral administration of serial doses of diazoxide.

Weight loss. Diazoxide.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Visiting Tomishiro Central Hospital at the Diabetes and Lifestyle Disease Center. 2. Written informed consent. 3. Waist length is more than 85cm of male or 90cm of female.

Exclusion criteria

Exclusion criteria: Diabetes mellitus. Pt of Heart, Lung, Liver, Kidney or GI disease. Subjects of pregnancy or of allergy against diazoxide.

Design outcomes

Primary

Measure	Time frame
Adverse events and side effects. Suppression of excessive insulin secretion without hyperglycemia.	—

Secondary

Measure	Time frame
Body weight loss. Shortening of waist length.	—

Contacts

Public Contacttoma shimon

Yuuai Medical Center

toma.tomishiro.hp@gmail.com+81-98-850-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026